US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say
Executive Summary
CDER's OHOP, as well as relevant CBER and CDRH staff, should be folded into OCE, which should have final sign-off on all oncology products, ASCO and Friends of Cancer Research say.
You may also be interested in...
US FDA Plans Rare Disease Center Of Excellence, But Not "That" Kind Of COE
A COE modeled after the Oncology Center of Excellence, which stakeholders had proposed, is not in the works, but rather a more virtual structure.
Oncology Center Of Excellence Comes Of Age at US FDA
Our infographic details organizational structure and management of FDA’s first inter-center institute; five of 11 associate director positions are being filled on an acting basis.
Center Of Excellence Not Best Model For US FDA Rare Disease Program, Woodcock Says
Center for Drug Evaluation and Research Director says rare disease reviews need multiple specialists, which likely would not fit into a centralized rare disease review group.